UnknownPhase 4

Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume

China600 participantsStarted 2011-03

Plain-language summary

This multicentre, open-label, single-arm Study is to evaluate the effect of Rosuvastatin 20 mg 76 weeks on coronary atherosclerosis plaque versus baseline in Chinese coronary heart disease (CHD) patients with hyperlipidemia by measuring the plaque volume using a 64 slice spiral CT. Effect on blood lipids, hsCRP and Carotid intima-media thickness (CIMT) is also evaluated.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. History of myocardial infarction.
✓. CHD confirmed by coronary angiography.
✓. Excercise ECG positive for CHD or perfusion defect
✓. One or more main branch of coronary artery stenosis ≥ 50% confirmed by CT scanning.
✓. Diameter of coronary artery lesion ≥2mm, length ≥5mm; distance between multiple lesions \>1cm
✓. Plaque density \<100HU, no calcification
✓. Vascular stenosis (20～60%) caused by plaques
✓. Plaque thickness \>1mm

What they're measuring

Change from baseline in coronary atherosclerosis plaque volume using a 64 slice spiral CT at 76 weeks

Timeframe: 76 weeks

Trial details

NCT IDNCT01382277

SponsorPeking University First Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-04

Contact for this trial

Jie Jiang, MD

86-10-66551383 jiangjie@medmail.com.cn

View on ClinicalTrials.gov More Hyperlipidemia trials